About the Program
Program Overview
While an increasing number of options are available or in development for effectively treating patients with HCV infection, many clinicians find it challenging to keep abreast of important developments in HCV therapeutics. To address this problem, this CME dinner program series will use case studies to highlight and discuss the relative merits and clinical significance of new findings in HCV medicine presented at the 65th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2014).
Because the focus of the dinner programs will be on case studies, participants will need to be familiar with data from AASLD 2014 that may be applied and discussed. Therefore, prior to attending a dinner program, participants will view an Internet presentation that independently reports on, summarizes and discusses the key data presented at AASLD 2014. As a result of this blended learning approach, participants will not only gain an increased understanding of key data presented at AASLD 2014, they will also be better prepared to address their HCV patients' health needs and provide optimal care, which should improve adherence, increase individualized care, reduce adverse effects and drug-drug interactions, and improve quality of life.
Target Audience
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HCV infection.
Learning Objectives
After completing this activity, the participant should be better able to:
- Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2014
-
Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at AASLD 2014
to improve patient care
-
Engage patients and colleagues in discussion on studies and data presented at AASLD 2014 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC
Program Dates and Locations
Tuesday, Nov 18, 2014
Baltimore, MD |
Tuesday, Dec 2, 2014
New York, NY |
Thursday, Nov 20, 2014
Boston, MA |
Wednesday, Dec 3, 2014
Los Angeles, CA |
Thursday, Nov 20, 2014
Chicago, IL |
Thursday, Dec 4, 2014
Houston, TX |
Tuesday, Dec 2, 2014
Miami, FL |
Thursday, Dec 4, 2014
San Francisco, CA |
Course Director
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Faculty
Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
|
Sammy Saab, MD
Professor of Medicine and Surgery
The Pfleger Liver Institute
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
|
Maurizio Bonacini, MD
Director, HIV-Liver Clinic
Department of Transplantation
California Pacific Medical Center
San Francisco, California |
John M. Vierling, MD, FACP, FAASLD
Professor of Medicine and Surgery
Chief of Hepatology
Director of Advanced Liver Therapies
Baylor College of Medicine
Baylor St. Luke's Medical Center
Houston, Texas
|
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease
Professor of Medicine
University of Miami's School of Medicine
Miami, Florida
|
|
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (AACME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Sunshine Act
As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.
Supported by an unrestricted educational grant from Gilead Sciences Medical Affairs.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2014 and it is not sanctioned by AASLD 2014.
|